Immunomodulation Programs
Autoimmune Disorders
Key Facts
About Fosun Pharma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive pharmaceutical and healthcare conglomerate that has evolved from a Chinese pharmaceutical company into a global innovation leader. The company operates through diversified business segments including pharmaceutical manufacturing, vaccines, medical devices, medical diagnostics, and healthcare services, while also maintaining significant positions in pharmaceutical distribution through its Sinopharm investment. Fosun Pharma has established technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy, with particular focus on first-in-class and best-in-class drug development. The company's commitment to innovation is demonstrated through its substantial R&D expenditure of RMB 5.554 billion in FY2024 and its successful development of globally recognized products like Artesun®, which has treated over 56 million severe malaria patients worldwide.
View full company profileTherapeutic Areas
Other Autoimmune Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira | Royalty Pharma | Commercial |
| Adalimumab Biosimilar | Glenmark Pharmaceuticals | Phase 3 |
| Autoimmune Disease Programs | TScan Therapeutics | Discovery |
| Autoimmune Diagnostics (Immco) | Trinity Biotech | Approved/Commercial |
| TYK2 Pseudokinase Inhibitor | A2A Pharma | Preclinical |